J&J’s Gorsky Promises Prioritization Of OTC Business
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson’s Q2 was another quarter of flat consumer products growth, with the return of some OTCs to market delayed until 2013. In his quarterly earnings call debut, CEO Alex Gorsky emphasized the firm’s commitment to diversification and restoring the supply of OTC products.